Effect of antiinflammatory eye drops (topical nepafenac 0.3%) on retinal thickness (central macular thickness) after cataract surgery in patients with diabetes: A randomized controlled trial
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications
- Registration Number
- CTRI/2023/03/050650
- Lead Sponsor
- pondicherry institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All diabetic patients in the age group 40yrs and above, will be undergoing routine cataract surgery.
Exclusion Criteria
•Preexisting macular diseases/ macular oedema
•Recent intraocular surgery other than cataract surgery for 3 months
•Intra operative complications during the surgery
•Allergic or hypersensitive to NSAIDS, corticosteroids
•Chronic and recurrent inflammatory eye diseases.
•Use of any eye drops in last three months.
•Diseases causing macular edema other than diabetes are age related macular degeneration, Retinal venous occlusion, Coats disease, Radiation retinopathy, choroidal tumors and retinitis pigmentosa Other drugs like chloroquine, tamoxifen and interferon can induce macular edema.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the effect of perioperative nepafenac 0.3% on central macular thickness after uneventful cataract surgery in diabetesTimepoint: Follow up day 1, day-7, day 28 <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method To determine the association of the effect of nepafenac (0.3%) with post cataract surgery visual acuity.Timepoint: Follow up day 1, day-7, day 28 <br/ ><br> <br/ ><br>